




METRO

Gordon College insults our intelligence



BUSINESS

Two golfers face US charges of insider trading



BUSINESS

The saga of Demou Market Basket

Dicerna plans to relocate to Cambridge

By [Chris Reidy](#) | GLOBE STAFF JULY 15, 2014

[Dicerna Pharmaceuticals Inc.](#) has entered into a lease agreement for a new 37,186-square-foot corporate headquarters in the Alewife neighborhood of Cambridge, a broker involved in the transaction said Tuesday.

The broker is [Cushman & Wakefield](#), which represented the landlord, [King Street Properties LLC](#), in the transaction.

CONTINUE READING BELOW ▼

Currently based in Watertown, Dicerna is working in the field of RNA interference. RNA interference, or RNAi, is a gene-silencing technology that has the potential for developing drugs to treat cancers and other diseases.

In January, Dicerna began selling stock shares to the public. On their first day of trading, Dicerna shares soared nearly 207 percent, the largest opening-day gain of any company since the Chinese search engine Baidu.com went public in 2005.

King Street Properties, a Waltham-based real estate investment management firm, recently purchased two laboratory buildings in Alewife that had previously been owned and occupied by the giant drug maker Pfizer Inc.

In June, [Pfizer relocated much of its local operations to a new research facility in Kendall Square](#). King Street Properties is currently in the process of renovating the now vacant

buildings, and one of those buildings --- 87 CambridgePark Drive --- will be Dicerna's new home.

“Dicerna’s interest in relocating to 87 CambridgePark Drive, immediately after our purchase of the building, validates our investment in the West Cambridge market,” King Street Properties principal Stephen Lynch said in a statement. “The quality of the asset, combined with strong market fundamentals, makes us very optimistic about the future of this building.”

In a separate statement, Dicerna’s chief business officer Jim Weissman added: “The goal in Dicerna’s search for a new headquarters location was to identify an office and laboratory space that would enhance our open and collaborative corporate culture. The scale and setting of 87 CambridgePark Drive offers Dicerna an expanded footprint in the dynamic Cambridge biotech community that is very much consistent with who we are as a company.”

Cushman & Wakefield executive director Mark Winters, senior director David Townsend, and senior director Juliette Reiter made up the team that represented King Street Properties.

Dicerna Pharmaceuticals was represented by T3 Advisors president Roy Hirshland and T3 Advisors senior vice president Mike Shreve.

Chris Reidy can be reached at reidy@globe.com.